Titlebook: Drug-Coated Balloons; Applications in Inte Bernardo Cortese Book 2019 Springer Nature Switzerland AG 2019 drug-eluting balloon.angioplasty

incredulity

明智的人

背叛者

The Use of Drug-Coated Balloons for Patients with In-Stent Restenosis,ocardial infarction, a complex scenario associated with plaque rupture and a large thrombus burden where the acute results of stent implantation may not be optimal. At last DCB have been used in selected de novo lesions providing satisfactory angiographic results obtained upon dilatation.

厭倦嗎你

奇怪

歡呼

Writing C Modules with Inline::C, the use of DCB is associated with a reduction in recurrent restenosis and target lesion revascularization (TLR) at least at 1 year after plain old balloon angioplasty (POBA). The available data strongly support the use of DCB to reduce SFA ISR recurrence.

right-atrium

Strong, Em, and Other Phrase Elementsthough further investigations to evaluate endothelization patterns and long-term clinical outcomes are required, bailout DES implantation is a reasonable strategy to manage suboptimal DCB results, especially when treating complex lesions.

temperate

Technical Insights on Drug-Coated Balloons,ayed vessel healing [3, 4]. Current guidelines recommend the use of prolonged double antiplatelet therapy (DAPT) following DES implantation which may become problematic in specific clinical settings where a shorter DAPT period is desired (i.e., high-bleeding-risk patients) [5].

的是兄弟

Potential Clinical Advantages of Drug-Coated Balloon in Specific Clinical Settings,ce for an indication of DCB angioplasty in the treatment of metallic in-stent restenosis, further clinical scenarios have been investigated for the use of DCB with promising results for some of them. Current data on clinical scenarios with potential advantages of DCB angioplasty are summarized in this chapter.

過(guò)度

Drug-Coated Balloon in Superficial Femoral Artery In-Stent Restenosis, the use of DCB is associated with a reduction in recurrent restenosis and target lesion revascularization (TLR) at least at 1 year after plain old balloon angioplasty (POBA). The available data strongly support the use of DCB to reduce SFA ISR recurrence.